Zoetis Meets Q2 Street Views on EPS and Revenues

Zoetis, a purveyor of medicines for animals, Tuesday reported Q2 earnings and revenues in line with Street views. Zoetis reported Q2 adjusted EPS of $0.53, in line with Street views as compiled by Capital IQ, and above the $0.49 reported a year earlier.

The company reported revenues of $1.27 billion, also in line with Street views, and above the $1.21 billion reported a year earlier. In 2017 full-year guidance, Zoetis expects revenue of between $5.15 billion and $5.25 billion and adjusted EPS between $2.30 and $2.37, vs. the Street views of $5.19 billion in revenues and EPS of $2.33.